Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 1 Standardized Patient -Centered Medication Review in 
Home Hospice  
This title should include, where possible, information on the participants, condition being evaluated, and 
intervention(s) studied.  
Unique Protocol Identification Number:  
National Clinical Trial (NCT) Identified Number: [STUDY_ID_REMOVED]  
Principal Investigator: Jennifer Tjia  
Sponsor:  
"Sponsor" indicates an institution, foundation, or individual who takes responsibility for and initiates a 
clinical investigation; often times this is the university with which the Principal Investigator is affiliated.  
Grant Title: PILOT STUDY OF STANDARDIZED PATIENT -CENTERED MEDICATION 
REVIEW (SPECTORX) IN HOME HOSPICE  
Grant Number: R21 AG060017  
Funded by: NIA  
Version Number: v.1.004  
30 January 2020  
All versions should have a version number and a date. Use an international date format (e.g.,YYYY -MM -
DD [2017 -12-21] or write out the month (e.g., 21 December 2017).  
For the initial submission of a protocol to the I RB, indicate "Not applicable; this is the first version of the 
protocol." in the table below. For any subsequent amendment being submitted to the IRB, add details of 
the specific changes that are being implemented in the amendment. Please note that Section  10.4 is a 
high -level summary of all formal protocol versions/amendments.  
 
 
Summary of Changes from Previous Version:  
Affected Section(s)  Summary of Revisions Made  Rationale  
8.4 - Unanticipated 
problems  Included language to address 
possible situation that participants 
may use telephone surveys to ask 
clinical questions  To ensure participant safety, this 
change establishes a procedure to 
escalate clinical questions to the 
clinical hospice team in a timely  and 
systematic manner  
      
 
 
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 2 Table of Contents  
Statement of Compliance  ................................ ................................ ................................ ................................ ..............  4 
Investigator's Signature ................................ ................................ ................................ ................................ ..............  4 
1 Protocol  Summary  ................................ ................................ ................................ ................................ .......................  6 
1.1 Synopsis  ................................ ................................ ................................ ................................ ................................  6 
1.2 Schema  ................................ ................................ ................................ ................................ ...............................  10 
1.3 Schedule of Activi ties ................................ ................................ ................................ ................................ .........  11 
2 Introduction ................................ ................................ ................................ ................................ ...............................  13 
2.1 Study Rationale  ................................ ................................ ................................ ................................ ..................  13 
2.2 Background  ................................ ................................ ................................ ................................ ........................  13 
2.3 Risk/Benefit Assessment  ................................ ................................ ................................ ................................ .... 14 
2.3.1 Known Potential Risks  ................................ ................................ ................................ ................................ . 14 
2.3.2 Known Potential Benefits  ................................ ................................ ................................ ............................  14 
2.3.3 Assessment of Potential Risks and Benefits ................................ ................................ ................................  14 
3 Objectives and Endpoints ................................ ................................ ................................ ................................ ..........  16 
4 Study Design  ................................ ................................ ................................ ................................ ..............................  18 
4.1 Overall Design  ................................ ................................ ................................ ................................ ....................  18 
4.2 Scientific Rationale for Study Design  ................................ ................................ ................................ .................  18 
4.3 Justification for Intervention  ................................ ................................ ................................ ..............................  19 
4.4 End -of-Study Definition  ................................ ................................ ................................ ................................ ...... 19 
5 Stud y Population  ................................ ................................ ................................ ................................ .......................  20 
5.1 Inclusion Criteria  ................................ ................................ ................................ ................................ ................  20 
5.2 Exclusion Criteria  ................................ ................................ ................................ ................................ ................  20 
5.3 Lifestyle Considerations  ................................ ................................ ................................ ................................ ..... 21 
5.4 Screen Failures  ................................ ................................ ................................ ................................ ...................  21 
5.5 Strategies for Recruitment and Retention  ................................ ................................ ................................ .........  21 
6 Study Intervention(s) or Experimental Manipulation(s)  ................................ ................................ ...........................  23 
6.1 Study Intervention(s) or Experimental Manipulation(s) Administration  ................................ ...........................  23 
6.1.1 Study Intervention or Experimental Manipulation Description  ................................ ................................ . 23 
6.1.2 Administration and/or Dosing  ................................ ................................ ................................ ....................  23 
6.2 Fidelity  ................................ ................................ ................................ ................................ ................................  23 
6.2.1 INTERVENTIONIST TRAINING AND TRACKING  ................................ ................................ ............................  23 
6.3 Measures to Minimize Bias: Randomization and Blinding ................................ ................................ .................  24 
6.4 Study Intervention/Experimental Manipulation Adherence  ................................ ................................ .............  24 
6.5 Concomitant Therapy  ................................ ................................ ................................ ................................ .........  24 
6.5.1 Rescue Therapy  ................................ ................................ ................................ ................................ ...........  24 
7 Study Intervention/Experimental Manipulation Discontinuation and Participant Discontinuation/Withdrawal  ... 25 
7.1 Discontinuation of Study Intervention/Experimental Manipulation  ................................ ................................ . 25 
7.2 Participant Discontinuation/Withdrawal from the Study  ................................ ................................ ..................  25 
7.3 Lost to Follow -Up ................................ ................................ ................................ ................................ ...............  26 
8 Study Assessments and Procedures  ................................ ................................ ................................ ..........................  27 
8.1 Endpoint and Other Non -Safety Assessments  ................................ ................................ ................................ ... 27 
8.2 Safety Assessments  ................................ ................................ ................................ ................................ ............  27 
8.3 Adverse Events and Serious Adverse Events  ................................ ................................ ................................ ..... 28 
8.3.1ADVERSE EVENTS  ................................ ................................ ................................ ................................ .........  28 
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 3 8.4 Unanticipa ted Problems ................................ ................................ ................................ ................................ ..... 29 
9 Statistical Considerations  ................................ ................................ ................................ ................................ ..........  30 
9.1 Statistical Hypotheses  ................................ ................................ ................................ ................................ ........  30 
9.2 Sa mple Size Determination  ................................ ................................ ................................ ................................  30 
9.3 Populations for Analyses  ................................ ................................ ................................ ................................ .... 30 
9.4 Statistical Analyses  ................................ ................................ ................................ ................................ .............  30 
9.4.1 General Approach  ................................ ................................ ................................ ................................ .......  30 
9.4.2 Analysis of the Primary Endpoint(s)  ................................ ................................ ................................ ............  30 
9.4.3 Analysis of the Secondary Endpoint(s) ................................ ................................ ................................ ........  31 
9.4.4 Safety Analyses ................................ ................................ ................................ ................................ ............  31 
9.4.5 Baseline Descriptive Statistics  ................................ ................................ ................................ .....................  31 
9.4.6 Planned Interim Analyses  ................................ ................................ ................................ ............................  31 
9.4.7 Sub -Group Analyses  ................................ ................................ ................................ ................................ .... 32 
9.4.8 Ta bulation of Individual Participant Data  ................................ ................................ ................................ ... 32 
9.4.9 Exploratory Analyses  ................................ ................................ ................................ ................................ ... 32 
10 Supporting Documentation and Operational Considerations  ................................ ................................ ................  33 
10.1 Regulatory, Ethical, and Study Oversight Considerations ................................ ................................ ................  33 
10.1.1Informed Consent Process  ................................ ................................ ................................ .........................  33 
10.1.2Study Discontinuation and Closure  ................................ ................................ ................................ ............  34 
10.1.3Confidentiality and privacy  ................................ ................................ ................................ ........................  35 
10.1.4Future Use of Stored Specimens and Data  ................................ ................................ ................................  36 
10.1.6Safety Oversight  ................................ ................................ ................................ ................................ .........  36 
10.1.7Clinical Monitoring  ................................ ................................ ................................ ................................ ..... 37 
10.1.8Qu ality Assurance and Quality Control  ................................ ................................ ................................ ...... 37 
10.1.9Data Handling and Record Keeping  ................................ ................................ ................................ ...........  38 
10.1.10 Protocol Deviations  ................................ ................................ ................................ ................................ . 38 
10.1.11 Publication and Data Sharing Policy  ................................ ................................ ................................ .......  39 
10.1.12 Conflict of Interest Policy  ................................ ................................ ................................ ........................  39 
10.2 Additional Considerations  ................................ ................................ ................................ ................................  40 
10.3 Abbreviations and Special Terms  ................................ ................................ ................................ .....................  40 
10.4 Protocol Amendment History  ................................ ................................ ................................ ..........................  41 
11 References  ................................ ................................ ................................ ................................ ...............................  43 
References  ................................ ................................ ................................ ................................ ............................  43 
 
 
 
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 4 STATEMENT OF COMPLIANCE  
Provide a statement that the trial will be conducted in compliance with the protocol, International 
Council on Harmonisation Good Clinical Practice (ICH GCP) and applicable state, local and federal 
regulatory requirements. Each engaged institution must have a current Federal -Wide Assurance (FWA) 
issued by the Office for Human Research Protections (OHRP) and must provide this protocol and the 
associated informed consent documents and recruitment mater ials for review and approval by an 
appropriate Institutional Review Board (IRB) or Ethics Committee (EC) registered with OHRP. Any 
amendments to the protocol or consent materials must also be approved before implementation. Select 
one of the two statements  below. If the study is an intramural  NIH study, use the second statement 
below:  
1. The trial will be carried out in accordance with International Council on Harmonisation Good 
Clinical Practice (ICH GCP) and the following:  
o United States (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR Part 
46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812).  
National Institutes of Health (NIH) -funded investigators and clinical trial site staff who are 
responsible f or the conduct, management, or oversight of NIH -funded clinical trials have 
completed Human Subjects Protection and ICH GCP Training.  
OR 
2. The trial will be conducted in accordance with International Council on Harmonisation Good 
Clinical Practice (ICH GCP),  applicable United States (US) Code of Federal Regulations (CFR), and 
the [specify NIH Institute or Center (IC) [ Terms and Conditions of Award. The Principal 
Investigator will assure that no deviation from, or changes to the protocol will take place 
witho ut prior agreement from the funding agency and documented approval from the 
Institutional Review Board (IRB), and the Investigational New Drug (IND) or Investigational 
Device Exemption (IDE) sponsor, if applicable, except where necessary to eliminate an 
immediate hazard(s) to the trial participants. All personnel involved in the conduct of this study 
have completed Human Subjects Protection and ICH GCP Training.  
For either option above, the following paragraph would be included:  
The protocol, informed conse nt form(s), recruitment materials, and all participant materials will 
be submitted to the IRB for review and approval. Approval of both the protocol and the consent 
form(s) must be obtained before any participant is consented. Any amendment to the protocol  
will require review and approval by the IRB before the changes are implemented to the study. 
All changes to the consent form(s) will be IRB approved; a determination will be made regarding 
whether a new consent needs to be obtained from participants who p rovided consent, using a 
previously approved consent form.  
INVESTIGATOR'S SIGNATURE  
Principal Investigator or Clinical Site Investigator:  
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 5 Signed:    Date:    
Name*:   Jennifer Tjia  
Title*:   Principal Investigator  
 
 
Investigator Contact Information:  
Affiliation*:   UMass Medical School  
Address:   368 Plantation Street, Worcester, MA 01605  
Telephone:   774-455-3538  
Email:   jennifer.tjia@umassmed.edu  
 
For multi -site studies, the protocol should be signed by the clinical site investigator who is responsible  
for the day to day study implementation at his/her specific clinical site:  
Signed:    Date:    
Name:   Jennifer Tjia  
Title:   Principal Investigator  
Affiliation:   UMass Medical School  
  
Signed:    Date:    
Name:   Margaret Clayton  
Title:   Co-Investigator  
Affiliation:   University of Utah  
  
Signed:    Date:    
Name:   Susan DeSanto -Madeya  
Title:   Co-Investigator  
Affiliation:   Boston College  
 
 
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 6 1 PROTOCOL SUMMARY  
1.1 SYNOPSIS  
Title:  Standardized Patient -Centered Medication Review in 
Home Hospice  
Grant Number:  R21 AG060017  
Study Description:  Background  
    Over 1.3 million Americans aged 65 years and older receive 
hospice services annually and 45% are cared for at home.5 These 
patients are prescribed an average of 10 -12 medications daily6 7 
8and have progressively declining organ function that increases their 
risk of drug -related harm9 10. Furthermore, many take questionabl y 
beneficial medications11 12 13until death while simultaneously being 
prescribed an increasing number of end -of-life (EOL) symptom 
management drugs. This changing combination of medications 
contributes to stress and confusion for family caregivers (FCG) w ho 
are responsible their management and administration.14 3  
  
Study Design  
   This protocol describes a pilot multi -site cluster randomized trial of 
a behavioral education intervention to standardize hospice clinician 
approach to medication management sup port for family caregivers 
of patients in home hospice vs attention control of an educational 
handout about medication management for older adults education 
from the NIA.   The primary outcome if feasibility and acceptability of 
the trial as measured by tri al enrollment and completion.   Secondary 
outcomes include family caregiver medication administration 
burden, family caregiver satisfaction with care, polypharmacy, 
medication regimen complexity, patient quality of life, patient 
symptom burden, adverse even ts including hospitalizations and 
emergency department and adverse drug withdrawal events.   
Objectives*:  Primary 
Objective:  To determine, among patients admitted to 
home hospice with life -limiting illness, the 
acceptability and feasibility of enrollment 
and completion of a trial of a medication 
support program delivered by home hospice 
clinical staff.  
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 7 Secondary 
Objective:  Secondary analysis will investigate the 
following outcomes:  
• Family caregiver medication burden, as 
measured by the Family Caregiver 
Medication Administration Hassle Scale.  
• Family caregiver satisfaction with care, as 
determined by likelihood to recommend  
• Polypharmacy  
• Potentially inappropriate medication use, 
as determined by a modified Medication 
Appropriateness Index  
• Medication regimen complexity, as 
measured by the Medication Regimen 
Complexity Scale  
• Medication changes  
• Adverse drug withdrawal events, as 
measured by a single item single item 
measure of change in medication since last 
visit and associated symptom change  
• Patient Quality of life (QOL), as measured 
by the McGill QOL Questionnaire (MQOLQ)  
• Patient Symptoms, as measured by the 
Edmonton Symptom Assessment System 
(ESAS)  
• Performance status, as measured by the 
Karnofsky Performance Status sale (KPS)  
• Unanticipated Events (whether study -
related or not), as measured by time to 
first important event, consisting of:  
o admission to a hospital for any 
reason  
o admission to an emergency 
department for any reason  
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 8 • Overall survival, as measured by time -to-
death  
  
 
Endpoints*:  Primary Endpoint:  Trial completion  
Secondary 
Endpoints:  As described in Secondary Objectives  
 
Study Population:  Eligible participants are adults aged 65 years and older with 
advanced life -limiting illness with an estimated prognosis of 1-
6 months who are prescribed 5 or more medications and their 
family caregivers.   
Phase* or Stage:  Feasibility Trial  
Description of Sites/Facilities 
Enrolling Participants:  Hospice Sites. EOL practices vary regionally. 13 15Thus, we are 
partnering with two large, geographically distinct home hospice 
agencies to begin exploring the generalizability of SPECTORx 
nationally. Each agency has multiple offices serving different 
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 9 local regions within their states. Care Dimensions 
(Massachusetts) h as 2 offices serving 4 counties in Eastern 
MA, and CNS Home Health & Hospice (Utah) has 10 offices 
throughout Utah.  
Description of Study 
Intervention/Experimental 
Manipulation:  The study intervention is a patient -centered medication review and 
FCG support  program called “ Standardized PatiEnt-CenTered 
medicati On Review (SPECTO Rx) in Home Hospice”. This intervention 
combines 3 innovative, complementary, educational programs that, 
together, train hospice staff to create a comprehensive, patient -
centered, medication management plan. These evidence -based 
tools equip hospice staff: 1. to systematically identify medications 
that can be stopped or tapered using STOPPFrail (Screening Tool of 
Older Persons Prescriptions) criteria; 2. to disconti nue medications 
appropriately; and 3. to educate and support FCGs with medication 
administration and management challenges. The SPECTORx program 
also creates an online learning community for hospice clinicians to 
promote ongoing education and practice chan ge. 
Study Duration*:  Estimated study duration from earliest enrollment to 
completion of data collection is 12 months.  
Participant Duration:  Estimated time it will take for each individual participant to 
complete all study -related tasks (i.e. time from enrollment to 
patient death, discharge from hospice, or end of study) is 6 
months.  
 
 
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 10 1.2 SCHEMA  
 
 
 
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 11 1.3 SCHEDULE OF ACTIVITIES  
  STUDY PERIOD  
  Screening / 
Enrollment  
  Post -allocation  Close -out 
TIMEPOINT    
Baseline 
(Day 0 -3) 
  2 weeks  4 weeks    
  
6 weeks  8 weeks and 
monthly  24 weeks or 
death  
ENROLLMENT  
Eligibility screening  x           
Informed consent  x           
FEASIBILITY  
SPECTORx Intervention              
Attention Control              
ASSESSMENTS (Source/Items)  
FCG/Demographics  x           
FCG/Family Caregiver 
Medication Administration 
Hassle Scale  x  x  x x x    
FCG/Potential medication 
related symptom change    x x x x   
FCG/Patient Centered 
Medication 
Communication  x x x x x   
FCG/Satisfaction with Care 
(Likelihood to recommend)            x 
EMR/ PT Demographics  x           
EMR/ PT Primary Hospice 
Admitting Diagnosis*  x           
EMR/ PT Comorbid Illness*  x           
EMR/PT Medications*  x x x x x   
EMR/PT KPS*  x x x x x   
EMR/PT Survival*    x x x x   
EMR/PT Health resource 
utilization (hospital 
admissions, emergency 
department visits)*    x x   
x x   
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 12 EMR/Potential Drug Related 
Problem Screen  x x x x x   
Patient/Potential Drug 
Related Problem    x   x  ( & 
monthly 
thereafter)      
Patient/MQOLQ  x x x x x   
Patient/ESAS  x x x x x   
 
 
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 13 2 INTRODUCTION  
2.1 STUDY RATIONALE  
Need for a Comprehensive, Patient -Centered, Medication Review and FCG Support Program  
  
A tremendous challenge  in home hospice care is ensuring that medication prescribing is appropriately 
aligned to patients’ goals of care and that medications are appropriately managed by FCGs.  
  
There are no intervention studies addressing medication appropriateness in home hospice . Our 
literature review16 found one uncontrolled, retrospective study in geriatric palliative care that reviewed 
and simplified  regimens by reducing unnecessary drug use by 65% (from 1.7 to 0.6 per patient).17 
Investigators reported that 74% of patients use d at least 1 unnecessary medication (defined as drugs 
with lack of indication, lack of effectiveness, or prolonged duration of therapy). Their study provided 
“proof of concept” that it is possible to systematically review and simplify medications in geriat ric 
palliative care.17 However, such studies have focused on geriatrics18 19 20 21 22 23and nursing homes,24 25 
and not home hospice.  
  
Few studies examine FCG medication management needs .14 3 26 27 FCGs have many challenges, including 
dealing with patients’ non -adherence, deciding which medications to give, juggling administration times 
and monitoring for side effects.14 3 Furthermore, patient symptom outcomes depend on appropriate 
medication administration. (Figure 1) The implication is that high -quality, patient -centered care needs to 
address both  medication appropriateness and FCG medication management support.  
  
Therefore, we propose a novel approach that trains hospice staff to (a) regularly review, simplify, and 
align  patients’ prescribed medic ations with their goals of care as their illness progresses , 16 and (b) 
support  FCGs’ with education that empowers them to understand each medication’s use, develop skills 
for safe administration, and understand when stopping medications may be beneficial .3 26  
 
 
2.2 BACKGROUND  
Polypharmacy for Home Hospice Patients is Burdensome, Harmful and Costly  
Over 1.3 million Americans aged 65 years and older receive hospice services annually and 45% are cared 
for at home.5 These patients are prescribed an average of  10-12 medications daily6 7 8 and have 
progressively declining organ function that increases their risk of drug -related harm.9 Furthermore, 
many take questionably beneficial medications11 12 13 until death while simultaneously being prescribed 
an increasin g number of end -of-life (EOL) symptom management drugs.8 This changing combination of 
medications contributes to stress and confusion for family caregivers (FCG) who are responsible who are 
responsible for patient medication management and administration.14 3 
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 14   
Family (Informal) Caregivers Find Managing Complex Home Hospice Medication Regimens Stressful  
Family (informal) caregivers are defined as “any relative, partner, friend or neighbor who has a 
significant personal relationship with, and provides a broad range of assistance for [an older 
person]”.  4 Hospice is a particularly challenging setting for FCGs because they are responsible for 
complicated medication administration tasks that are usually reserved for licensed healthcare 
professiona ls.28  An estimated 44 million adults, mostly women, provide this informal (i.e. unpaid) 
care.  29 They often feel inadequately prepared for this responsibility  30 and have fears about doing 
something wrong.28 30  
 
 
2.3 RISK/BENEFIT ASSESSMENT  
2.3.1 KNOWN P OTENTIAL RISKS  
The risks and costs vs benefits of reducing polypharmacy for patients with advanced disease and their 
family caregivers remains a genuine clinical uncertainty.   Multiple studies support the use of myriad 
individual chronic disease medication s, such as statins, in elderly adults with appropriate indication. 
However, the benefit of continuing chronic disease medications after hospice admission on quality of 
life, family caregiver medication hassle, or patient survival is unknown.   Simplifying m edication regimens 
through a process of depresribing is one remedy to medication complexity as death approaches, but 
may be associated with potential risk of stress to family caregivers about making decisions regarding 
stopping medications and additional p otential risk of adverse drug withdrawal events after stopping 
medications - a particular concern when abruptly stopping medications with long half lives that are 
known to require tapering protocols.  
2.3.2 KNOWN POTENTIAL BENEFITS  
Multiple studies support reduction of polypharmacy in elderly patients with multi -morbidity. Less is 
known to support the benefit of medication discontinuation among patients in hospice. One exception is 
the question of benefit from stopping statins used for primary prevention amo ng eldelry patients with 
advanced illness, a question addressed in a randomized controlled trial of statin discontinuation by 
Kutner et al.   These data show that statin discontinuation does not contribute to shorted survival, and 
may be associated with imp roved quality of life.   
2.3.3 ASSESSMENT OF POTENTIAL RISKS AND BENEFITS  
Polypharmacy has known patient burden and associated patient side effects. This is attributable to the 
accumulation of individual medication effects, and known drug -drug interactions resulting from complex 
medication regimens. For patients with life -limiting conditions who take one or more chronic disease 
medications along with symptom directed therapies, the balance of medication efficacy vs burden 
remains unclear.   Finally, the psych ological impact of using or discontinuing chronic disease medications 
in the setting of advanced life -limiting illness is largely unknown.   Patients may feel relief when not 
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 15 taking as many pills, anticipating the potential for fewer side effects, and payin g less medication costs 
for medications not covered by hospice yet desired by the family. Conversely, there may be increase 
worry or distress when discontinuing a medication that a patient and their family was told would need 
to be taken for the rest of th eir lives.   
 
 
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 16 3 OBJECTIVES AND ENDPOINTS  
OBJECTIVES  ENDPOINTS  JUSTIFICATION FOR 
ENDPOINTS  PUTATIVE 
MECHANISMS OF 
ACTION  
Primary  
Feasibility and 
Acceptability  • Intervention 
Delivery to Hospice 
Staff  
• Patient and Family 
Caregiver 
Recruitment Goals  
• Completion of FCGs 
Assessments  
• Completion of 
Patient 
Assessments  
• Time for completing 
FCG assessments  
• Time for completing 
Patient 
Assessments  
• Yield of FCG 
Eligibility Criteria  
• Yield of Patient 
Eligibility Criteria  • Measurements of 
Intervention Uptake  
• Measures of 
Recruitment Yield  
• Measure of 
Outcome 
Assessment Success    
Secondary  
Efficacy and Safety  
• FCG Burden  
• Medication 
Regimen 
Complexity  
• Patient -Centered 
Medication 
Communication  • Primary Outcome 
for trial  
• Patient medication 
burden     
• Quality of 
prescribing for 
patients    
   
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 17 OBJECTIVES  ENDPOINTS  JUSTIFICATION FOR 
ENDPOINTS  PUTATIVE 
MECHANISMS OF 
ACTION  
• Potentially 
Inappropriate 
Medications, as 
measured by 
modified 
Medication 
Appropriateness 
Index  
• Medication changes  
• Patient QOL, as 
measured by McGill 
QOL Questionnaire  
• Patient Symptoms, 
as measured by 
Edmonton 
Symptom 
Assessment System 
(ESAS)  
• Overall Survival  
• Suspected 
Unexpected Serious 
Adverse Reactions 
(SUSAR)  
• Drug  Related 
Problems    
  
• Key patient outcome  
  
  
  
• Key patient outcome  
  
  
  
• Key patient outcome  
• Assessment of risk 
for study population  
• Risk assessment for 
intervention  
Tertiary/Exploratory  
        
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 18 4 STUDY DESIGN  
4.1 OVERALL DESIGN  
A pilot, single -blinded, cluster randomized, pragmatic trial of the SPECTO Rx intervention.  
We will compare outcomes within and across 2 large, multi -office, hospice agencies from Utah and 
Massachusetts. Within each hospice agency, we will randomize 1 office to intervention and 1 office to 
attention control. Target enrollment is 30 FCG -patient dyads per agency (n=15 intervention, n=15 
control), for a total trial target  of n=60 FCG -dyads of patients aged ≥65 years, with an estimated life 
expectancy of >1 month, and polypharmacy (defined as ≥5 regularly scheduled daily medications).  
 
 
4.2 SCIENTIFIC RATIONALE FOR STUDY DESIGN  
This is a controlled study to evaluate the eff ect of a medication review, education and communication 
intervention on improving medication administration burden by family caregivers in home hospice. The 
unit of randomization is the team within a hospice agency, the intervention is aimed at the hospice  
clinicians, and patient and family caregivers are the units of analysis. We randomize at the level of the 
hospice to reduce cross -contamination at the clinician level.   
  
Study Design. We will compare outcomes within and across 2 large hospice agencies us ing a cluster 
randomized trial study design. Within each hospice agency, we will recruit 30 eligible FCG -patient dyads 
(total n=60) of patients ≥65 years old, an estimated life expectancy >1 month, and polypharmacy 
(defined as ≥5 regularly scheduled daily medications). [ Eligibility Criteria  for details]  
Hospice Sites. EOL practices vary regionally.13 15 Thus, we are partnering with two large, geographically 
distinct home hospice agencies to begin exploring the generalizability of SPECTORx nationally. Each 
agency has multiple offices serving different local regions within their states. Care Dimensions 
(Massachusetts) has 2 offices serving 4 counties in Eastern MA, and CNS Home Health & Hospice (Utah) 
has 10 offices throughout Utah. Combined, they had over 5,0 00 hospice admissions in 2016. Both have 
recently participated in a research studies. (see Letters of Support ) 
Randomization and Attention Control.  Within each of the 2 hospice agencies, we will randomize 1 
office to intervention and 1 to control status. T arget enrollment is 15 FCG -patient dyads at each office 
(total 30 FCG -patient dyads per hospice agency). As the attention control, we will refer staff in control 
offices to the NIA’s website on “Medicines and Medication Management”  37 to review content and  
materials for use in FCG support.   
 
 
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 19 4.3 JUSTIFICATION FOR INTERVENTION  
High -quality, patient -centered care about medication management in hospice needs to address both 
medication appropriateness and FCG medication management support. We propose a novel approach 
that trains hospice staff to (a) regularly review, simplify, and align  patients’ prescribed medications with 
their goals of care as their illness progresses,  16 and (b) support  FCGs’ with education that empowers 
them to understand each medication’s use, develop skills for safe administration, and understand when 
stoppin g medications may be beneficial.  3 26 
  
  
 
 
4.4 END -OF-STUDY DEFINITION  
A FCG participant is considered to have completed the study if he or she has completed the baseline 
assessment, and at least the 2 week assessment and the post -death follow -up assessment (or at 6 
months if patient survives 6 months after hospice admission).  
  
A patient participant is considered to have completed the study if he or she has completed the baseline 
assessment, and at least the 2 -week assessment.  
  
The end of the stu dy is defined as completion of the 6 -month follow -up assessment shown in the 
Schedule of Activities (SoA), Section 1.3 . 
 
 
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 20 5 STUDY POPULATION  
5.1 INCLUSION CRITERIA  
Participants (patients, FCGs, and clinical hospice staff) will be recruited for both interve ntion and control 
arms.  
  
FCG-Patient Dyads.  
  
Patient  - Eligible patients are newly admitted home hospice enrollees, aged ≥65 years old with: 1. 
advanced life -limiting illness; 2. an estimated life expectancy of >1 month; 3. recent functional status 
decline (defined as change in Karnofsky Performance Status [KPS]  1 to < 80% in prior 3 months); 4. 
polypharmacy (defined as ≥ 5 regularly scheduled medications [excluding antimicrobials]); 5. cognitive 
ability to provide informed consent based on a Short Porta ble Mental Status Questionnaire (SPMSQ) 
score ≥6  2 OR, with a legally authorized representative who is willing and able to provide proxy consent. 
These variables are easily assessed on hospice intake forms on admission.  
  
FCG – FCGs are eligible if: they s elf-identify as “usually” or “always” providing care to the eligible 
patient; are English -speaking; have telephone access; and have cognitive ability to participate.  3 Family is 
operationally defined “any relative, partner, friend or neighbor who has a sig nificant personal 
relationship with, and provides a broad range of assistance.”  4 
  
Hospice Clinicians  - 
  
Hospice clinicians are eligible if : nurses, social workers, chaplains and medical directors deliver care or 
communicate with home hospice patients in the course of their primary hospice -related job 
responsibility; pharmacists are eligible if their primary responsibility is to oversee safety of prescribing of 
medications to home hospice patients or coordination of medication -related decisions  with hospice 
prescribers.  
 
 
5.2 EXCLUSION CRITERIA  
A patient who meets any of the following criteria will be excluded from participation in this study:  
1. Life expectancy of < 1 month  
2. Age < 65 years old  
3. Cognitively unable to provide informed consent AND no legally authorized representative (LAR) to who is 
willing to provide proxy consent  
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 21 4. No family caregiver  
 
 
5.3 LIFESTYLE CONSIDERATIONS  
 
 
5.4 SCREEN FAILURES  
We will not consent participants to do not meet eligibility criteria. It is possible that consenting , enrolled 
patients may die quickly after enrollment despite meeting eligibility criteria. This is not unexpected for 
this study population.    
  
  
 
 
5.5 STRATEGIES FOR RECRUITMENT AND RETENTION  
Patient and family caregiver participants will be recruited th rough the participating home hospice 
clinical sites.   Each site minimally includes a dedicated Site Investigator and Research Assistant capable 
of enrolling in and conducting the study.  
  
The total enrollment is up to 60 consenting patient -FCG dyads. Within each of the 2 hospice agencies, 
we will randomize 1 office to intervention and 1 to control status. Target enrollment is 15 FCG -patient 
dyads at each office (total 30 FCG -patient dyads per hospice agency).  
  
Hospice clinician participants will be re cruited at each hospice site. In cooperation with hospice 
administrative leaders, we will present the study to the hospice clinical teams and invite teams 
randomized to the intervention to complete the online education training intervention about 
medicatio n review, education, and deprescribing.   
  
The Site PI will develop study -specific recruitment strategies in consultation with the local hospice 
administration.   Site RA and CRCs and other study staff will attend an introductory training program 
covering r esearch related -communication, ethics, recruitment planning and implementation.  
  
The screening and recruitment algorithms will be developed for each site, delineating expected 
processes and highlighting potential hurdles so that effective solutions can be  developed.   Key messages 
for the recruitment call/visit, supporting study diagrams, recruiting scripts, strategies for working with 
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 22 bereaved family members, and simplified consent language will be developed. Tools will be practiced 
through role plays:   refresher role plays will be repeated periodically during the study to ensure quality 
and consistency. Recruitment metrics will be monitored on a regular basis and will including screening 
eligibility, study completion, study withdrawal rates; progress will be presented to Site Investigators and 
staff.   If a study site should encounter particular difficulty with enrollment, the study team may conduct 
a site visit to review obstacles and devise solutions, presenting results for review to the existing study 
stakeholder panel.  
  
Site specific screening will follow this general scheme, but may be adapted (as described herein) to local 
workflow procedures to minimize impact on clinical care delivery:  
In general, hospice staff (i.e. front -line hospice nurses or loca l administrative staff) will preliminarily 
screen eligible patients on their daily hospice census list and, at their discretion within the first week 
after the hospice admission visit, provide an  IRB-approved generic brochure  about research in hospice 
and palliative care; if there is interest in learning more about the study, the patient and family caregiver 
will also be given an IRB -approved study -specific brochure. A variation at some hospices routinely places 
an IRB-approved generic brochure  about resear ch in hospice and palliative care in the hospice admission 
packet along with information about how to contact the hospice to opt -out of being screened and 
contacted for research, or similarly routinely provides patients and families to opt -out of being scr eened 
for research based on the local hospice's forms and policies.  We will work with local hospice leadership 
to identify the most appropriate approach for their system. Then, a list of eligible participants will be 
identified and confirmed by a CITI -trained RA who will examine the daily admissions for hospice to 
identify participants who meet eligibility criteria among patients who have indicated interest in hearing 
about the study to front -line staff (or, as applicable, has not opted -out to being screene d for research. 
This will generate a final list of eligible patient and family, and the hospice will then forward contact 
information to the study team among eligible participants indicating in the form of an authorization to 
contact form.   
  
  
The Site RA  will follow -up to lead recruitment efforts.   
 
 
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 23 6 STUDY INTERVENTION(S) OR EXPERIMENTAL MANIPULATION(S)  
6.1 STUDY INTERVENTION(S) OR EXPERIMENTAL MANIPULATION(S) ADMINISTRATION  
6.1.1 STUDY INTERVENTION OR EXPERIMENTAL MANIPULATION DESCRIPTION  
  
Intervention:   We will present the SPECTORx educational intervention to clinical hospice staff 
randomized to the intervention.   This is comprised of 3 x 20 -25 minute online in -service modules about 
systematic, patient -centered, medication review, education al support for family caregivers about 
medication administration, and deprescribing of potentially inappropriate medications.  The intervention 
patient and family caregiver participants will be given a study -specific notebook including a blank 
notepad, a bl ank medication tracking sheet, and printed information about the Medications in Older 
Adult website, as well as printed guidance from the NIA's Medicine's and Medication Management 
website ( https://www.nia.nih.gov/health/topics/medicines -and-medication -management ) about "What 
Do I Need to Tell the Nurse and Doctor?", and clinical information handouts about medications 
commonly used in hospice (e.g. Haldol, Morphine, Un derstanding Nausea, Understanding Pain and 
Symptoms).  
  
Attention control:   We will refer clinical hospice staff randomized to control offices to "Medications in 
Older Adults" website sponsored by the American Geriatrics Society’s Health in Aging Foundatio n. 
(https://www.healthinaging.org/medications -older -adults)   Based on personal preferences, these 
materials can be shared via electronic link or the information can be printed and distr ibuted in paper 
form to patients and their family caregivers. The attention control patient and family caregiver 
participants will be given a study -specific notebook including a blank notepad, a blank medication 
tracking sheet, and information about the Me dications in Older Adult website.  
  
At the end of the trial, staff in control offices will be offered the SPECTORx educational intervention 
training.  
  
6.1.2 ADMINISTRATION AND/OR DOSING  
  
Staff will be referred to this attention control resources one time, but will be able to access the 
resources as many times as they deem clinically appropriate for the care of their patients.  
 
 
6.2 FIDELITY  
6.2.1 INTERVENTIONIST TRAINING AND TRACKING  
  
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 24 We will track completion of online learning of the t hree 20 -25 minute SPECTORx educational modules, 
including self -assessment quizzes by tracking completion online and by asking consenting participants to 
complete brief self -assessments before and after the educational intervention. Study staff will 
periodi cally check in with hospice clinical staff to inquire about adherence to the study intervention. We 
will also track fidelity be asking FCGs of consenting hospice nurses brief questions about whether 
hospice staff conducted medication reviews, offered educa tion and support about medication 
administration and management, and discussed the option of deprescribing medications that are 
potentially inappropriate.  
 
 
6.3 MEASURES TO MINIMIZE BIAS: RANDOMIZATION AND BLINDING  
Randomization is at the level of the offi ce location within each hospice agency.   
  
Outcomes assessments will be blinded with withholding intervention assignment data from the clinical 
research coordinator responsible for data collection related to the measurement of patient and family -
caregiver outcomes and from the adjudication team responsible for measuring ADE and ADWEs.   
 
 
6.4 STUDY INTERVENTION/EXPERIMENTAL MANIPULATION ADHERENCE  
The intervention is a medication support care intervention delivered by hospice clinical team, led by the 
hospice  nurse.   Hospice teams are randomized to SPECTORx intervention or attention control of 
standard American Geriatric Society/NIA funded educational materials of medication management for 
older adults.  
 
 
6.5 CONCOMITANT THERAPY  
  
6.5.1 RESCUE THERAPY  
  
 
 
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 25 7 STUDY INTERVENTION/EXPERIMENTAL MANIPULATION DISCONTINUATION AND 
PARTICIPANT DISCONTINUATION/WITHDRAWAL  
7.1 DISCONTINUATION OF STUDY INTERVENTION/EXPERIMENTAL MANIPULATION  
The study intervention, which targets hospice clinical staff, will be delivered one time at the beginning of 
the study and will be delivered to any new clinical staff joining the intervention site teams.   We will 
inform the clinical sites of the end of the study when we 3 months after completion of study enrollment 
to allow for adequate, uncontaminated, collection of outcome data for all participants.   
  
When a subject discontinues study procedures will be completed as indicated by the study protocol.   If a 
clinically significant finding is identified (including, but not limi ted to changes from baseline) after 
enrollment, the investigator or qualified designee will determine if any change in participant 
management is needed. Any new clinically relevant finding will be reported as an adverse event (AE).  
  
The data to be collect ed at the time of study intervention discontinuation will include the following:  
• The reason(s) for discontinuing the participant from the intervention, and methods for determining the 
need to discontinue  
• If the participant is due to complete assessments wi thin 2 weeks of being discontinued from the study 
intervention, those assessments will be administered at the time of discontinuation; if the next scheduled 
assessments are more than 2 weeks from the discontinuation date, the discontinued participant will wait 
for the next scheduled assessment. Thereafter, the participant will be included in all future scheduled 
assessments, even though not participating in the intervention.  
 
 
7.2 PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM THE STUDY  
Participants (family ca regivers and patients) are free to withdraw from participation in the study at any 
time upon request.  
  
An investigator may discontinue a participant from the study for the following reasons:  
• Lost-to-follow up; unable to contact subject (see Section 7.3, L ost to Follow -Up) 
• Any event or medical condition or situation occurs such that continued collection of follow -up study data 
would not be in the best interest of the participant or might require an additional treatment that would 
confound the interpretation  of the study  
• The participant meets an exclusion criterion (either newly developed or not previously recognized) that 
precludes further study participation  
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 26 The reason for participant discontinuation or withdrawal from the study will be recorded on the 
[spe cify] Case Report Form (CRF).  
  
Clinical staff participants (nurses, social workers, chaplains, physicians, pharmacists) area also free to 
withdraw from the study at any time. Consenting clinical participants who are randomized but do not 
receive the study intervention may be replaced. Consenting participants who are randomized and 
receive the study intervention, and subsequently withdraw, or are discontinued from the study, will be 
replaced when possible.  
 
 
7.3 LOST TO FOLLOW -UP 
A participant will be considered lost to follow -up if study staff are unable to contact the participant after 
at least 3 attempts.  
The following actions must be taken if a participant fails complete study assessments:    
• The site will attempt to contact the participant and ascer tain if the participant wishes to and/or should 
continue in the study  
• Before a participant is deemed lost to follow -up, the investigator or designee will make every effort to 
regain contact with the participant (where possible, 3 telephone calls and, if ne cessary, a certified letter 
to the participant’s last known mailing address or local equivalent methods). These contact attempts will 
be documented in the participant’s medical record or study file.  
• Should the participant continue to be unreachable, he or she will be considered to have withdrawn from 
the study with a primary reason of lost to follow -up 
 
 
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 27 8 STUDY ASSESSMENTS AND PROCEDURES  
8.1 ENDPOINT AND OTHER NON -SAFETY ASSESSMENTS  
The endpoint of the study is either patient death, disenrollment from hosp ice, or completion of 6 
months of follow -up after study enrollment.  
 
 
8.2 SAFETY ASSESSMENTS  
In accordance with applicable regulatory requirements and principles for the ethical conduct of 
research, a Safety Officer will be appointed by the NIA to oversee the safety of study participants.  
  
Because the study population has, per the eligibility cri teria, a limited expected prognosis of less than 
one year, death and the preceding associated development of symptoms related to the natural 
progression of disease are expected. Because the study setting is home hospice, hospitalizations related 
to the nat ural progression of disease are expected to be unusual.   However, deaths, hospitalizations, 
and emergency department visits will be monitored.  
  
Because the focus of the trial educational intervention focuses on medication -related management, 
review and su pport, medication changes and symptom changes potentially related to drug related 
problems (DRPs) will be monitored, including potential DRPs present upon study enrollment which, by 
definition, are not related to the research.  
  
Medication changes will be identified by collecting medication lists every 2 weeks and iteratively 
identifying changes between lists. DRPs will be monitored by a trained research assistant who will 
screen the medical record using a Screening Algorithm of Potential Drug Related Pr oblems at study 
enrollment and every 2 weeks up to 2 months for a retrospective chart review, and then monthly up to 6 
months.   These medical record will be reviewed for new clinical events, symptoms, abnormal lab events 
and drug levels, new reported drug allergies or drug associated problems identified by clinicians. 
Secondarily, a trained research assistant will also conduct a screening telephone interview with patients 
(or their caregiver, if patient is unable to participate) for potential DRPs using a m ethod by 
Chrischilles31 at 2 weeks and monthly  thereafter.  
  
To ensure that potential DRPs, emergency department visits, hospitalizations and deaths are indeed 
unrelated to the research, these will be closely monitored by the study's Event Classification P harmacist 
(ECP) comprised of a pharmacist using a procedure described below in Section 8.3.  
  
  
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 28  
 
8.3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS  
8.3.1  ADVERSE EVENTS  
  
Any event due to the presence or progression of illness that a patient had on study enrol lment will not 
be considered an adverse event (AE), including changes in symptoms, hospitalizations, emergency 
department presentations, and death more likely related to disease progression than not related to 
disease progression. Only events more likely n ot related to known underlying illness will be considered 
an AE.  
  
If such an event is also related to the research and is unanticipated, regardless of its level of severity, 
this would require expedited (prompt) reporting to the local IRB in keeping with its reporting 
requirements for a suspected unanticipated problem involving risks to subjects or others (suspected 
UPIRTSO).  
  
AEs are classified as to whether or not they are serious (SAE), namely life threatening (resulting in 
hospitalization, emergency d epartment presentation or death), leading to permanent disability or 
judged a SAE by the site PI. AEs will be graded according to seriousness, and then designated as more 
likely expected or unexpected (yes/no), and more likely related or unrelated to the r esearch (yes/no). 
Other characteristics of the AE to be recorded include date identified, diagnosis, outcome and date 
resolved.  
  
SAEs will be classified as to whether or not they are a Suspected Unexpected Serious Adverse Reaction. 
(SUSAR)   SUSARs are def ined as events that are a suspected adverse reaction AND serious AND 
unexpected. This approach focuses the Safety Officer's and IRB's attention on potentially study 
participating -related events rather than on a large number of anticipated events that are p art of normal 
disease progression and unrelated to the intervention.   If a SUSAR, then expedited reporting and 
processes must be followed, as outlined below.   If not a SUSAR, standard reporting for AEs is followed 
(for all AEs and SAEs), unless, as describ ed above, the event meets the definition of a suspected 
Unanticipated Problems Involving Risks to Subjects or Others (UPIRTSO). An event can be a SAE, but not 
a SUSAR (e.g. a person hospitalized for hip fracture and not attributable to underlying known ill ness, but 
not suspected to be related to the study intervention).  
  
The ECC will review a pre -specified proportion of all hospitalizations and deaths. The ECC will determine 
if the hospitalization/death or drug related problem (DRP) was an expected event, SAE, or SUSAR. 
Results will be reported to the Safety Officer and the NIA Project Officer.  
  
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 29 Cumulative aggregated AE data will be presented to the Safety Officer and the NIA Project Officer, along 
with tabulated outcomes data. This includes AEs, SAEs and SUSARs, plus survival, health resource 
utilization, and patient reported outcomes.  
  
The Study PI is also responsible for contacting the NIH grant program officer in the event that any action 
resulting in temporary or permanent suspension of the trial occu rs.  (Because this trial does not involve 
any investigational medication, the action would be limited to an IRB - or investigator -initiated 
suspension or discontinuation of the study.)  
  
  
  
  
 
 
8.4 UNANTICIPATED PROBLEMS  
See discussion of UPIRTSO above in 8.3.  
  
Further, there is the possibility that the patient and/or family caregiver will ask clinical questions (e.g. 
about symptom management) of the study research assistant during a  telephone interviews for study -
related outcomes assessment.   If this occurs, the research assistant will   1. provide the hospice triage 
phone number to the participant and direct him/her to call about their clinical questions and 2. call the 
hospice triage phone number directly, inform hospice that the participant had clinical questions, and 
request a call back to the patient/family caregiver.   
 
 
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 30 9 STATISTICAL CONSIDERATIONS  
9.1 STATISTICAL HYPOTHESES  
• Primary Endpoint(s): For this exploratory study, the primary endpoints are: acceptability and feasibility of 
the SPECTO Rx intervention by hospice stakeholders; feasibility of a brief, standardized, ‘interest in 
research’ screen upon hospice admission to refer FCG -patient dyads for recruitment; acceptability, 
burden and completion of FCG assessments (FCG Medication Administr ation Hassle Scale  32 at baseline, 2 
weeks, 4 weeks, 6 weeks, 8 weeks, and monthly).  
• Secondary Efficacy Endpoint(s): medication regimen complexity index scores33 for chronic daily 
medications and prevalence of potentially inappropriate medications (baselin e, 2 weeks, 4 weeks, 6 
weeks, 8 weeks, and monthly and death), patient quality of life, patient symptom burden  
 
 
9.2 SAMPLE SIZE DETERMINATION  
Sample Size Justification . In this exploratory study, we chose a sample size sufficient to enable a decision 
abou t feasibility.34 This sample size is larger than many pilot palliative care trials and sufficient to 
determine acceptability in each of the two hospice agencies.35 This sample size is also attainable. Target 
enrollment is 30 FCG -dyads at each hospice agenc y who, combined, have over 400 admissions a month. 
We lack power to establish efficacy for the intervention on outcomes.  
 
 
9.3 POPULATIONS FOR ANALYSES  
While we aim to enroll dyads of family caregivers and patients, the population for analysis include fami ly 
caregiver outcome separate from patient outcomes.  
 
 
9.4 STATISTICAL ANALYSES  
9.4.1 GENERAL APPROACH  
  
9.4.2 ANALYSIS OF THE PRIMARY ENDPOINT(S)  
Feasibility and Acceptability. We will use descriptive statistics to analyze quantitative feasibility 
outcomes . We will calculate the mean number of eligible patient -FCG dyads screened and enrolled per 
week, accrual, retention, and training completion. We will use Chi -square (for compar isons of rates and 
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 31 proportions) and t -tests (for mean comparisons) to explore differences by site and participant 
characteristics, including sex.  
9.4.3 ANALYSIS OF THE SECONDARY ENDPOINT(S)  
A secondary goal of this pilot is to estimate preliminary interven tion treatment effect size for a large -
scale, R01 -funded trial. Comparisons will be made between the baseline and follow -up assessments, 
both within and across intervention and control sites. Descriptive analyses will establish data 
distributions for conti nuous outcomes (e.g. FCG Hassles Scale). We will use linear mixed effects models 
to account for cluster randomization for continuous outcomes. Clusters are hospice agencies, offices 
within agencies, clinicians within office, and patients within clinicians/ nurses. Even with small samples, 
we can explore the relationship between change in measures (e.g. # PIMs) and FCG/patient factors. 
Mixed effects models are robust with small sample sizes and adjust for correlations from repeated 
measures within individuals  and from clustering.     
     Missing Data . Descriptive analyses will characterize missing data frequency and examine associations 
with key characteristics (e.g. admitting diagnosis, race). Variables associated with missingness will be 
included in analyses  as covariates to account for possible effects from the missing pattern (missing at 
random).  36 
9.4.4 SAFETY ANALYSES  
  
Safety reports will be sent to the Safety Officer and Project Officer at every 3 months and will include a 
detailed analysis of study pr ogress, data and safety issues, including interim analyses as described in 
9.4.6.  
  
  
9.4.5 BASELINE DESCRIPTIVE STATISTICS  
  
1. Baseline characteristics of the patients and family caregivers.  
  
9.4.6 PLANNED INTERIM ANALYSES  
1. Recruitment by week/month;  
2. Treatm ent phase of patients & family caregivers (screened, enrolled, follow -up phase);  
3. Completeness of data (assessments completed, % of expected forms submitted, % of submitted forms 
passing edit);  
4. Missed assessments and missing information within assessments;  
5. Summary of adverse events by type;  
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 32 6. Summary of adverse events by body system;  
7. Summary of actual medication changes;  
8. Listing of adverse events (including duration, severity, seriousness, relatedness, action taken, resolution);  
9. Descriptive information for each endpoint without statistical testing except at designated interim 
monitoring points if requested by the DSMB, including # and details of medication changes for each 
patient during the study;  
10. Compliance information (completion of interv ention training by clinical staff); and  
11. Quality control analyses.  
9.4.7 SUB -GROUP ANALYSES  
  
Analyses by intervention and control status.  
9.4.8 TABULATION OF INDIVIDUAL PARTICIPANT DATA  
  
9.4.9 EXPLORATORY ANALYSES  
  
 
 
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 33 10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  
10.1 REGULATORY, ETHICAL, AND STUDY OVERSIGHT CONSIDERATIONS  
10.1.1  INFORMED CONSENT PROCESS  
10.1.1.1  CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED TO 
PARTICIPANTS  
To alleviate the burden of obtainin g written consent from these typically home -bound patients and their 
family caregivers, we will use a telephone based consent procedure. That is, we will obtain a waiver of 
written documentation of informed consent for this minimal risk participation study  for family 
caregivers and patients, since their involvement requests only access to medical records and completion 
of telephone questionnaires.  
  
If a patient and family caregiver a potentially interested in study participation, they will be given a Fact 
Sheet by the hospice staff that summarizes the relevant information about the study, including the risks, 
benefits, and rights as a study participant. Hospice staff will not answer questions about the study 
consent, but will refer all questions to trained study staff who will be scheduled to call the patient within 
1 week of referral to the study staff. The fact sheets will describe the study in detail the study 
intervention, study procedures, and risks.  
  
Potentially eligible patients will be referred to t he study team. To minimize burden of making a 
unnecessary study enrollment calls to ineligible patients, we will request a HIPAA waiver for medical 
record review for the express purpose of confirming eligibility by the study team. If confirmed to be 
eligib le, the study team will call the patient and family caregiver to explain the study, answer any 
question about participation and the fact sheet, and to obtain telephone recorded consent.  
  
Persons with dementia will be given the opportunity to consent for themselves because cognitive 
impairment is not always associated with the lack of capacity to provide informed consent to participate 
in research. Study staff will explain the study and assess capacity to consent based on the standard 
decision -making capacity criteria of: (a) ability to communicate a yes or no decision; (b) ability to 
understand relevant information; (c) ability to appreciate the situation and its likely consequences; and 
(d) ability to manipulate information rationally. If the patient is unable to meet all 4 of these criteria, we 
will obtain consent from a legally authorized representative (LAR). Further, study staff will obtain 
consent from the LAR for persons with a documented dementia severity of FAST 6 or greater as this 
indicates severe dementia with limited speech ability, or individuals has been ruled incompetent by a 
court of law or with documentation by a qualified practitioner in the medical record that the individual 
lacks capacity to make the decision to participate i n the proposed study.  
  
Utah and Massachusetts hospice sites will provide lists of individuals who are authorized to consent 
when the patient ins unable to consent on their own behalf. In Utah this includes any married person for 
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 34 a spouse and any person 18  years of age or older for his or her parent who is unable to reason of age, 
physical or mental condition, to provide such consent. In Massachusetts this includes a health care agent 
or guardian.  
  
The LAR will be provided with the description of the resea rch study and informed of their role and 
obligation to protect the rights and welfare of the patient participant. The LAR must be informed that 
the obligation as a surrogate decision maker is to try to determine what the participant would decide if 
the par ticipant were able to make such decisions. In the case of this study, the patient's participation 
would be limited to providing HIPAA waiver for access to the medical record for data collection.  
  
The following consent materials are submitted with this pro tocol.  
• Study fact sheet for patients  
• Study fact sheet for family caregivers  
• Telephone consent script  
• Assessing Capacity to Consent Form  
  
10.1.2  STUDY DISCONTINUATION AND CLOSURE  
This study may be temporarily suspended or prematurely terminated if there is  sufficient reasonable 
cause. Written notification, documenting the reason for study suspension or termination, will be 
provided by the suspending or terminating party to study participants, the investigator and the funding 
agency (NIA). If the study is pr ematurely terminated or suspended, the Principal Investigator (PI) will 
promptly inform study participants, the IRB, and sponsor and will provide the reason(s) for the 
termination or suspension. Study participants will be contacted, as applicable, and be i nformed of 
changes to study visit schedule.  
  
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants  
• Demonstration of efficacy that would warr ant stopping  
• Insufficient compliance of study staff to the protocol (i.e., significant protocol violations)  
• Data that are not sufficiently complete and/or evaluable  
• Determination that the primary endpoint has been met  
• Determination of futility  
The study may resume once concerns about safety, protocol compliance, and data quality are 
addressed, and satisfy the funding agency, sponsor, IRB, or Safety Officer.  
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 35   
10.1.3  CONFIDENTIALITY AND PRIVACY  
Participant confidentiality and privacy is strictly held in trust by the participating investigators, their 
staff, the safety and oversight monitor(s), and the sponsor(s) and funding agency. This confidentiality is 
extended to the data being collected as part of this study. Data that could be used to identify a specific 
study participant will be held in strict confidence within the research team. No personally -identifiable 
information from the study will be released to any unauthorized third party without prior written 
approval of the sponsor/fundin g agency.  
  
All research activities will be conducted in as private a setting as possible.  
  
The study monitor, other authorized representatives of the sponsor, representatives of the Institutional 
Review Board (IRB), may inspect all documents and records required to be maintained by the 
investigator, including but not limited to, medical records (office, clinic, hospice or hospital) and 
pharmacy records for the participants in this study. The clinical study site will permit access to such 
records.  
  
The st udy participant’s contact information will be securely stored at each clinical site for internal use 
during the study. At the end of the study, all records will continue to be kept in a secure location for as 
long a period as dictated by the reviewing IRB,  Institutional policies, or sponsor requirements.  
  
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will 
be transmitted to and stored at the University of Massachusetts Medical School Data Coordinati ng 
Center. This will not include the participant’s contact or identifying information. Rather, individual 
participants and their research data will be identified by a unique study identification number. The study 
data entry and study management systems use d by clinical sites and by the University of Massachusetts 
Medical School Data Coordinating Center research staff will be secured and password protected. At the 
end of the study, all study databases will be de -identified and archived at the the University of 
Massachusetts Medical School Data Coordinating Center.  
  
Measures Taken to Ensure Confidentiality of Data Shared per the NIH Data Sharing Policies It is NIH 
policy that the results and accomplishments of the activities that it funds should be made avail able to 
the public (see https://grants.nih.gov/policy/sharing.htm). The PI will ensure all mechanisms used to 
share data will include proper plans and safeguards for the protection of privacy, confidentiality, and 
security for data dissemination and reuse (e.g., all data will be thoroughly de -identified and will not be 
traceable to a specific study participant). Plans for archiving and long -term preservation of the data will 
be implemented, as appropriate.  
  
Certificate of Confidentiality  
  
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 36 To further prote ct the privacy of study participants, the Secretary, Health and Human Services (HHS), 
has issued a Certificate of Confidentiality (CoC) to all researchers engaged in biomedical, behavioral, 
clinical or other human subjects research funded wholly or in part  by the federal government. Recipients 
of NIH funding for human subjects research are required to protect identifiable research information 
from forced disclosure per the terms of the NIH Policy (see https://humansubjects.nih.gov/coc/index). 
As set forth i n 45 CFR Part 75.303(a) and NIHGPS Chapter 8.3, recipients conducting NIH -supported 
research covered by this Policy are required to establish and maintain effective internal controls (e.g., 
policies and procedures) that provide reasonable assurance that th e award is managed in compliance 
with Federal statutes, regulations, and the terms and conditions of award. It is the NIH policy that 
investigators and others who have access to research records will not disclose identifying information 
except when the par ticipant consents or in certain instances when federal, state, or local law or 
regulation requires disclosure. NIH expects investigators to inform research participants of the 
protections and the limits to protections provided by a Certificate issued by th is Policy.  
  
10.1.4  FUTURE USE OF STORED SPECIMENS AND DATA  
Data collected for this study will be analyzed and stored at the University of Massachusetts Medical 
School Data Coordinating Center. After the study i s completed, the de -identified, archived data  will be 
transmitted to and stored at the Palliative Care Research Collaborative Data Repository, for use by other 
researchers including those outside of the study. Permission to transmit data to the Palliative Care 
Research Collaborative Data Repository w ill be included in the informed consent.  
  
During the conduct of the study, an individual participant can choose to withdraw consent to have data 
stored for future research. However, withdrawal of consent with regard to data storage may not be 
possible aft er the study is completed.  
  
When the study is completed, access to stud y data will be provided through the Palliative Care Research 
Collaborative Data Repository.  
  
10.1.6  SAFETY OVERSIGHT  
Safety oversight will be under the direction of a Safety Officer ( SO) who is a physician with relevant 
study and disease -specific expertise appointed by the study sponsor/NIA.   The SO is independent from 
the study conduct and free of conflict of interest, or measures should be in place to minimize perceived 
conflict of i nterest.   The SO will review the safety and data monitoring plan, informed consent 
documents, and participant recruitment and retention milestones.   At predetermined intervals (e.g. 
every 3 months) the study team will prepare safety reports to be reviewed by the SO and the NIA for 
recommendations for or against the trial's continuation, as well as any modification to the study.   The 
SO will be unblinded to safety data.   
  
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 37 10.1.7  CLINICAL MONITORING  
Clinical site monitoring will be conducted to ensure that the rights and well -being of trial participants are 
protected, that the reported trial data are accurate, complete, and verifiable, and that the conduct of 
the trial is in compliance with the currently approved protocol/amendment(s), with Internationa l 
Council on Harmonization Good Clinical Practice (ICH GCP), and with applicable regulatory 
requirement(s). Monitoring activities will be as follows:  
• Data Coordination and Quality Control . Data will be entered into REDCap data capture 
software, and then ex tracted to SAS for analysis. For all assessments, RAs will complete CRFs on 
paper for subsequent entry into REDCap. One part of the CRF will remain at the local site and 
the other part will be sent to the UMMS central study site for quality checking. The p roject 
biostatistician will conduct regular quality control analyses for missing data, internal consistency 
reliability, the number and type of forms failing to edit, and data distribution looking for 
outliers. We will conduct data audits by reviewing sele ct, high -risk, data [e.g. patient 
characteristics and medications] against source documents from every 5th patient enrolled (i.e. 
~10% sample). If systematic errors are detected, further data will be audited to determine the 
cause(s) and monitoring reports  will be generated and distributed accordingly.    
  
10.1.8  QUALITY ASSURANCE AND QUALITY CONTROL  
Each clinical site will perform internal quality management of study conduct, data and biological 
specimen collection, documentation and completion. All sites will follow a common quality management 
plan.  
  
Quality control (QC) procedures will be implemented as follows:  
  
Informed consent  - Study staff will review both the documentation of the consenting process as well as 
a percentage of the completed consent d ocuments. This review will evaluate compliance with GCP, 
accuracy, and completeness. Feedback will be provided to the study team to ensure proper consenting 
procedures are followed.  
  
Source documents and the electronic data  - Data will be initially captur ed on source documents (see 
Section 10.1.9, Data Handling and Record Keeping ) and will ultimately be entered into the study 
database. To ensure accuracy site staff will compare a representative sample of source data against the 
database, targeting key data  points in that review.  
  
Intervention Fidelity  Consistent delivery of the study interventions will be monitored throughout the 
intervention phase of the study. Procedures for ensuring fidelity of intervention delivery are described in 
Section 6.2.1, Inter ventionist Training and Tracking . 
  
Protocol Deviations  The study team will review protocol deviations on an ongoing basis and will 
implement corrective actions when the quantity or nature of deviations are deemed to be at a level of 
concern. Should indepe ndent monitoring become necessary, the PI will provide direct access to all trial 
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 38 related sites, source data/documents, and reports for the purpose of monitoring and auditing by the 
sponsor/funding agency, and inspection by local and regulatory authorities . 
  
10.1.9  DATA HANDLING AND RECORD KEEPING  
10.1.9.1   DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES  
Data collection will be the responsibility of the clinical trial staff at the site under the supervision of the 
site investigator. The investigator will b e responsible for ensuring the accuracy, completeness, legibility, 
and timeliness of the data reported.  
  
All source documents will be completed in a neat, legible manner to ensure accurate interpretation of 
data.  
Hard copies of the study visit worksheets will be provided for use as source document worksheets for 
recording data for each participant consented/enrolled in the study. Data recorded in the electronic 
case report form (eCRF) derived from source documents will be consistent with the data recorded on 
the source documents.  
  
Clinical data (including AEs, concomitant medications, and expected adverse reactions data) and clinical 
laboratory data will be entered into RedCAP, a 21 CFR Part 11 -compliant data capture system provided 
by the University of Ma ssachusetts Medical School DCC. The data system includes password protection 
and internal quality checks, such as automatic range checks, to identify data that appear inconsistent, 
incomplete, or inaccurate. Clinical data will be entered directly from the source documents.  
  
10.1.9.2   STUDY RECORDS RETENTION  
Study documents will be retained for a minimum of 2 years after the last approval of a marketing 
application in an International Council on Harmonization (ICH) region and until there are no pending or 
contemplated marketing applications in an ICH region or until at least 2 years have elapsed since the 
formal discontinuation of clinical development of the study intervention. These documents should be 
retained for a longer period, however, if r equired by local regulations. No records will be destroyed 
without the written consent of the sponsor/funding agency, if applicable. It is the responsibility of the 
sponsor/funding agency to inform the investigator when these documents no longer need to be  
retained.  
  
10.1.10 PROTOCOL DEVIATIONS  
This protocol defines a protocol deviation as any noncompliance with the clinical trial protocol, 
International Council on Harmonization Good Clinical Practice (ICH GCP), or Manual of Procedures 
(MOP) requirements. The noncompliance may be either on the part of the participant, the investigator, 
or the study site staff. As a result of deviations, corrective actions will be developed by the site and 
implemented promptly.  
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 39 These practices are consistent with ICH GCP:  
• Section 4.5 Compliance with Protocol, subsections 4.5.1, 4.5.2, and 4.5.3  
• Section 5.1 Quality Assurance and Quality Control, subsection 5.1.1  
• Section 5.20 Noncompliance, subsections 5.20.1, and 5.20.2.  
It will be the responsibility of the site investigator to use continuous vigilance to identify and report 
deviations within 10 working days of identification of the protocol deviation, or within 10 working days 
of the scheduled protocol -required activity. All deviations must be addressed in study source 
documents, reported to the UMass Med Data Coordinating Center. Protocol deviations must be sent to 
the reviewing IRB per their policies. The site investigator is responsible for knowing and adhering to the 
reviewing IRB requirements. Further details about the handling of protocol deviations will be included in 
the MOP.  
  
10.1.11 PUBLICATION AND DATA SHARING POLICY  
This study will be conducted in accordance with the following publication and data sharing polic ies and 
regulations:  
National Institutes of Health (NIH) Public Access Policy, which ensures that the public has access to the 
published results of NIH funded research. It requires scientists to submit final peer -reviewed journal 
manuscripts that arise fro m NIH funds to the digital archive PubMed Central upon acceptance for 
publication.  
  
This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH -Funded 
Clinical Trial Information and the Clinical Trials Registration and R esults Information Submission rule. As 
such, this trial will be registered at ClinicalTrials.gov, and results information from this trial will be 
submitted to ClinicalTrials.gov. In addition, every attempt will be made to publish results in peer -
reviewed j ournals. Data from this study may be requested from other researchers x years after the 
completion of the primary endpoint by contacting the University of Massachusetts Medical School or 
the PCRC data repository. Considerations for ensuring confidentiality  of these shared data are described 
in Section 10.1.3.  
  
10.1.12 CONFLICT OF INTEREST POLICY  
The independence of this study from any actual or perceived influence, such as by the pharmaceutical 
industry, is critical. Therefore any actual conflict of intere st of persons who have a role in the design, 
conduct, analysis, publication, or any aspect of this trial will be disclosed and managed. Furthermore, 
persons who have a perceived conflict of interest will be required to have such conflicts managed in a 
way that is appropriate to their participation in the design and conduct of this trial. The study leadership 
in conjunction with the University of Massachusetts Medical School   has established policies and 
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 40 procedures for all study group members to disclose all  conflicts of interest and will establish a 
mechanism for the management of all reported dualities of interest.  
 
 
10.2 ADDITIONAL CONSIDERATIONS  
Determination of ADE and ADWE  
  
  
 
 
10.3 ABBREVIATIONS AND SPECIAL TERMS  
ADE Adverse Drug Event  
ADWE  Adverse Drug Withdrawal Event  
AE Adverse Event  
ANCOVA  Analysis of Covariance  
CFR Code of Federal Regulations  
CLIA  Clinical Laboratory Improvement Amendments  
CMP  Clinical Monitoring Plan  
COC  Certificate of Confidentiality  
CONSORT  Consolidated Standards of Reporting Trials  
CRF Case Report Form  
DCC Data Coordinating Center  
DHHS  Department of Health and Human Services  
DSMB  Data Safety Monitoring Board  
DRE Disease -Related Event  
EC Ethics Committee  
eCRF  Electronic Case Report Forms  
ED Emergency Department  
FCG Family Caregiver  
FDA Food and Drug Administration  
FDAAA  Food and Drug Administration Amendments Act of 2007  
FFR Federal Financial Report  
GCP Good Clinical Practice  
GLP Good Laboratory Practices  
GMP  Good Manufacturing Practices  
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 41 GWAS  Genome -Wide Association Studies  
HIPAA  Health Insurance Portability and Accountability Act  
IB Investigator's Brochure  
ICH International Council on Harmonisation  
ICMJE  International Committee of Medical Journal Editors  
IDE Investigational Device Exemption  
IND Investigational New Drug Application  
IRB Institutional Review Board  
ISM Independent Safety Monitor  
ITT Intention -To-Treat  
LSMEANS  Least -squares Means  
MedDRA  Medical Dictionary for Regulatory Activities  
MOP  Manual of Procedures  
NCT National Clinical Trial  
NIH National Institutes of Health  
NIH IC  NIH Institute or Center  
OHRP  Office for Human Research Protections  
PI Principal Investigator  
QA Quality Assurance  
QC Quality Control  
QOL  Quality of Life  
SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
SMC  Safety Monitoring Committee  
SOA  Schedule of Activities  
SOC System Organ Class  
SOP Standard Operating Procedure  
UP Unanticipated Problem  
US United States  
  
 
 
10.4 PROTOCOL AMENDMENT HISTORY  
Version  Date  Description of Change  Brief Rationale  
        
        
        
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 42         
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
 
 
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 43 11 REFERENCES  
REFERENCES  
1. Schag CC, Heinrich RL, Ganz PA, Karnofsky performance status revisited: reliability, validity, and 
guidelines., J Clin Oncol. 1984 Mar;2(3):187 -93 
 
Pmid:20940385  
 
2. Pfeiffer E. A Short Portable Mental Status Questionnaire (SPMSQ). J Am Geriatr Soc. 1975;23:1975.  
 
Pmid:19030900  
 
3. Tjia J, Ellington L, Clayton MF, Lemay C, Reblin M, Managing Medications During Home Hospice Cancer 
Care: The Needs of Family Caregivers., J Pain Symptom Manage. 2015 Nov;50(5):630 -41 
 
Pmid:20652603  
 
4. National Coalition on Caregiving. Family Caregiver Alliance. www.caregiver.org. 2017.  
 
Pmid:25201279  
 
5. National Hospice and Palliative Care Organization. NHPCO’s Facts and Figures Hospice Care in America. 
2016. Available at: https://www.nhpco.org/sites/default/files/public/Statistics_Research/ 
2016_Facts_Figures.pdf. Accessed on October 5, 2017.  
 
Pmid:23175509  
 
6. McNeil MJ, Kamal AH, Kutner JS, Ritchie CS, Abernethy AP, The Burden of Polypharmacy in Patients Near 
the End of Life., J Pain Symptom Manage. 2016 Feb;51(2):178 -83.e2  
 
Pmid:26159294  
 
7. Dwyer LL, Lau DT, Shega JW, Medications That Older Adults in Hospice Care in the United States Take, 
2007., J Am Geriatr Soc. 2015 Nov;63(11):2282 -9 
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 44  
Pmid:12837714  
 
8. Currow DC, Stevenson JP, Abernethy AP, Plummer J, Shelby -James TM, Prescribing in palliative care as 
death approaches., J Am Geriatr Soc. 2007 Apr;55(4):590 -5 
 
Pmid:1530194  
 
9. Hanlon JT, Schmader KE, Koronkowski MJ, Weinberger M, Landsman PB, Samsa GP, Lewis IK, Adverse drug 
events in high risk older outpatients., J Am Geriatr Soc. 199 7 Aug;45(8):945 -8 
10. Steinman MA, Hanlon JT, Managing medications in clinically complex elders: "There's got to be a happy 
medium"., JAMA. 2010 Oct 13;304(14):1592 -601 
11. Riechelmann RP, Krzyzanowska MK, Zimmermann C, Futile medication use in terminally ill canc er 
patients., Support Care Cancer. 2009 Jun;17(6):745 -8 
 
Pmid:17397439  
 
12. Fede A, Miranda M, Antonangelo D, Trevizan L, Schaffhausser H, Hamermesz B, Zimmermann C, Del Giglio 
A, Riechelmann RP, Use of unnecessary medications by patients with advanced cancer: cross -sectional 
survey., Support Care Cancer. 2011 Sep;19(9):1313 -8 
13. Tjia J, Briesacher BA, Peterson D, Liu Q, Andrade SE, Mitchell SL, Use of medications of questionable 
benefit in advanced dementia., JAMA Intern Med. 2014 Nov;174(11):1763 -71 
14. Joyce BT, Lau DT, Hospice experiences and approaches to support and assess family caregivers in 
managing medications for home hospice patients: a providers survey., Palliat Med. 2013 Ap r;27(4):329 -38 
 
Pmid:23475597  
 
15. Mitchell SL, Teno JM, Roy J, Kabumoto G, Mor V, Clinical and organizational factors associated with 
feeding tube use among nursing home reside nts with advanced cognitive impairment., JAMA. 2003 Jul 
2;290(1):73 -80 
 
Pmid:19281937  
 
16. Tjia J, Velten SJ, Parsons C, Valluri S, Briesacher BA, Studies to reduce unnecessary medication use in frail 
older adults: a systematic review., Drugs Aging. 2013 May;30(5):285 -307 
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 45  
Pmid:22697490  
 
17. Suhrie EM, Hanlon JT, Jaffe EJ, Sevick MA, Ruby C M, Aspinall SL, Impact of a geriatric nursing home 
palliative care service on unnecessary medication prescribing., Am J Geriatr Pharmacother. 2009 
Feb;7(1):20 -5 
18. Schuling J, Gebben H, Veehof LJ, Haaijer -Ruskamp FM, Deprescribing medication in very elderly p atients 
with multimorbidity: the view of Dutch GPs. A qualitative study., BMC Fam Pract. 2012 Jul 9;13:56  
 
Pmid:23136399  
 
19. Woodward M, Bird M, Elliott R, Lourens H, Saunders R. Deprescribing: Arcieving Better Health Outcomes 
for Older People Through Reducing Medications. J Pharm Pract Res. 2003;Geriatric(33):323 -328.  
 
Pmid:20937924  
 
20. Scott IA, Gray LC, Martin JH, Pillans PI, Mitchell CA, Deciding when to stop: towards evidence -based 
deprescribing of drugs in older populations., Evid Based Med. 2013 Aug;18(4):121 -4 
 
Pmid:16137281  
 
21. Garfinkel D, Mangin D, Feasibility study of a systematic approach for discontinuation of multiple 
medications in older adults: addressing polypharmacy., Arch Intern Med. 2010 Oct 11;170(18):1648 -54 
 
Pmid:25385826  
 
22. Hajjar ER, Hanlon JT, Sloane RJ, Lindblad CI, Pieper CF, Ruby CM, Branch LC, Schmader KE, Unnecessary 
drug use in frail older people at hospital discharge., J Am Geriatr Soc. 20 05 Sep;53(9):1518 -23 
23. Reeve E, Andrews JM, Wiese MD, Hendrix I, Roberts MS, Shakib S, Feasibility of a patient -centered 
deprescribing process to reduce inappropriate use of proton pump inhibitors., Ann Pharmacother. 2015 
Jan;49(1):29 -38 
24. Liu LM. Deprescribin g: An approach to reducing polypharmacy in nursing home residents. J Nurse Pract. 
2014;10:136 -139.  
25. Harriman K, Howard L, McCracken R. Deprescribing medication for frail elderly patients in nursing homes: 
A survey of vancouver family physicians. B C Med J. 2014;56(9):436 -441.  
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 46  
Pmid:19465748  
 
26. Lau DT, Kasper JD, Hauser JM, Berdes C, Chang CH, Berman RL, Masin -Peters J, Paice J, Emanuel L, Family 
caregiver skills in medication ma nagement for hospice patients: a qualitative study to define a construct., 
J Gerontol B Psychol Sci Soc Sci. 2009 Nov;64(6):799 -807 
 
Pmid:20078242  
 
27. Lau DT, Masin -Peters J, Berdes C, Ong M, Perceived barriers that impede provider relations and 
medication delivery: hospice providers' experiences in nursing homes and private homes., J Palliat Med. 
2010 Mar;13(3):305 -10 
28. Lau DT, Berman R, Halpern L, Pickar d AS, Schrauf R, Witt W, Exploring factors that influence informal 
caregiving in medication management for home hospice patients., J Palliat Med. 2010 Sep;13(9):1085 -90 
29. McGuire DB, Grant M, Park J, Palliative care and end of life: the caregiver., Nurs Outl ook. 2012 Nov -
Dec;60(6):351 -356.e20  
30. Letizia M, Creech S, Norton E, Shanahan M, Hedges L, Barriers to caregiver administration of pain 
medication in hospice care., J Pain Symptom Manage. 2004 Feb;27(2):114 -24 
 
Pmid:9256846  
 
31. Chrischilles EA, Segar ET, Wallace RB, Self -reported adverse drug reactions and related resource use. A 
study of community -dwelling persons 65 years of age and older., Ann Intern Med. 1992 Oct 
15;117(8):634 -40 
32. Travis SS, Bernard MA, McAuley WJ, Thornton M, Kole T, Development of the family caregiver medication 
administration hassles scale., Gerontologist. 2003 Jun;43(3):360 -8 
33. McDonald MV, Peng TR, Sridharan S, Foust JB, Kogan P, Pezzin LE, Feldman PH, Automat ing the 
medication regimen complexity index., J Am Med Inform Assoc. 2013 May 1;20(3):499 -505 
34. Hertzog MA, Considerations in determining sample size for pilot studies., Res Nurs Health. 2008 
Apr;31(2):180 -91 
35. Jones TA, Olds TS, Currow DC, Williams MT, Feasib ility and Pilot Studies in Palliative Care Research: A 
Systematic Review., J Pain Symptom Manage. 2017 Jul;54(1):139 -151.e4  
36. Troxel AB, Fairclough DL, Curran D, Hahn EA, Statistical analysis of quality of life with missing data in 
cancer clinical trials., S tat Med. 1998 Mar 15 -Apr 15;17(5 -7):653 -66 
Standardized Patient -Centere d Medication Review in Home Hospice  Version 1.004  
Protocol  30 January 2020  
NIH Protocol Template for Behavioral and Social Sciences Research Involving Humans – v4.0 2018 -12-12 47 37. National Institute of Aging. Medicines and Medication Management. Available at: 
https://www.nia.nih.gov/health/topics/medicines -and-medication -management. Accessed October 12, 
2017.  